

# ACR Appropriateness Criteria<sup>®</sup> Pretreatment Staging of Colorectal Cancer

Expert Panel on Gastrointestinal Imaging: Kathryn J. Fowler, MD<sup>a</sup>, Harmeet Kaur, MD<sup>b</sup>, Brooks D. Cash, MD<sup>c</sup>, Barry W. Feig, MD<sup>d</sup>, Kenneth L. Gage, MD<sup>e</sup>, Evelyn M. Garcia, MD<sup>f</sup>, Amy K. Hara, MD<sup>g</sup>, Joseph M. Herman, MD, MSc<sup>b</sup>, David H. Kim, MD<sup>i</sup>, Drew L. Lambert, MD<sup>j</sup>, Angela D. Levy, MD<sup>k</sup>, Christine M. Peterson, MD<sup>l</sup>, Christopher D. Scheirey, MD<sup>m</sup>, William Small Ir, MD<sup>n</sup>, Martin P. Smith, MD<sup>o</sup>, Tasneem Lalani, MD<sup>p</sup>, Laura R. Carucci, MD<sup>q</sup>

#### **Abstract**

Colorectal cancers are common tumors in the United States and appropriate imaging is essential to direct appropriate care. Staging and treatment differs between tumors arising in the colon versus the rectum. Local staging for colon cancer is less integral to directing therapy given radical resection is often standard. Surgical options for rectal carcinoma are more varied and rely on accurate assessment of the sphincter, circumferential resection margins, and peritoneal reflection. These important anatomic landmarks are best appreciated on high-resolution imaging with transrectal ultrasound or MRI. When metastatic disease is suspected, imaging modalities that provide a global view of the body, such as CT with contrast or PET/CT may be indicated. Rectal cancer often metastasizes to the liver and so MRI of the liver with and without contrast provides accurate staging for liver metastases. This article focuses on local and distant staging and reviews the appropriateness of different imaging for both variants.

<sup>a</sup>Principal Author, Mallinckrodt Institute of Radiology, Saint Louis, Missouri.

<sup>b</sup>Co-author, University of Texas, MD Anderson Cancer Center, Houston, Texas. <sup>c</sup>University of South Alabama, Mobile, Alabama; American Gastroenterological Association.

<sup>d</sup>University of Texas MD Anderson Cancer Center, Houston, Texas; American College of Surgeons.

<sup>e</sup>Moffitt Cancer Center, Tampa, Florida.

<sup>f</sup>Virginia Tech Carilion School of Medicine, Roanoke, Virginia.

<sup>g</sup>Mayo Clinic, Scottsdale, Arizona.

<sup>h</sup>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.

<sup>i</sup>University of Wisconsin Hospital and Clinic, Madison, Wisconsin.

<sup>j</sup>University of Virginia Health System, Charlottesville, Virginia.

<sup>k</sup>Georgetown University Hospital, Washington, District of Columbia.

<sup>1</sup>Penn State Hershey Radiology, Hershey, Pennsylvania.

<sup>m</sup>Lahey Hospital and Medical Center, Burlington, Massachusetts.

<sup>n</sup>Stritch School of Medicine Loyola University Chicago, Maywood, Illinois.

<sup>o</sup>Beth Israel Deaconess Medical Center, Boston, Massachusetts.

PSpeciality Chair, Inland Imaging Associates and University of Washington, Seattle, Washington.

<sup>q</sup>Panel Chair, Virginia Commonwealth University Medical Center, Richmond, Virginia.

Corresponding author: Kathryn J. Fowler, MD, Attn: Dept of Radiology/ MRI, Mallinckrodt Institute of Radiology, 510 S Kingshighway Blvd, Saint Louis, MO 63110-1076; e-mail: fowlerk@mir.wustl.edu.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document. Reprint requests to: publications@acr.org

Dr. Small, Jr. reports personal fees and other from Zeiss Speaker's Bureau, other from Varian, outside the submitted work. Dr Gage reports travel support from GE Medical Systems and Siemens Healthcare, outside the submitted work. The other authors have no conflicts of interest related to the material discussed in this article.

Disclaimer: The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists, and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.

The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

Key Words: Appropriateness Criteria, Appropriate Use Criteria, AUC, colorectal cancer staging, rectal cancer imaging, rectal cancer MRI, rectal cancer transrectal ultrasound

J Am Coll Radiol 2017;14:S234-S244. Copyright © 2017 American College of Radiology

### ACR Appropriateness Criteria® Pretreatment Staging of Colorectal Cancer. Variants 1 and 2 and Table 1.

Variant 1. Rectal cancer. Locoregional staging.					
Radiologic Procedure	Rating	Comments	RRL		
MRI pelvis without and with IV contrast	9		0		
MRI pelvis without IV contrast	8	Noncontrast MRI is sufficient for T staging, though with and without is routinely used as well.	0		
US pelvis transrectal	8	For suspected early T-stage disease instead of MRI.	0		
CT abdomen and pelvis with IV contrast	5	May be appropriate if MRI cannot be performed and tumor is locally advanced.	***		
CT abdomen and pelvis without IV contrast	3	May be appropriate if MRI cannot be performed and tumor is locally advanced.	***		
CT abdomen and pelvis without and with IV contrast	3	May be appropriate if MRI cannot be performed and tumor is locally advanced.	***		
CT colonography	3	Low-dose CTC without IV contrast.	<b>₩₩</b>		

Note: Rating scale: 1, 2, 3 = usually not appropriate; 4, 5, 6 = may be appropriate; 7, 8, 9 = usually appropriate. CTC = CT colonography; IV = intravenous; RRL = relative radiation level; US = ultrasound.

Variant 2. Colorectal cancer. Staging for distant	metastases.		
Radiologic Procedure	Rating	Comments	RRL
CT chest abdomen pelvis with IV contrast	9		***
MRI abdomen and pelvis without and with IV contrast	8	MRI or CT can be used. Usually performed along with a chest CT.	0
FDG-PET/CT whole body	б		***
MRI abdomen and pelvis without IV contrast	5	Rarely used, but may be appropriate in situations when other exams cannot be performed due to contraindications. Usually performed along with chest CT.	0
CT chest abdomen pelvis without IV contrast	4	Only useful in a few very specific situations.	***
CT chest abdomen pelvis without and with IV contrast	3	Limited added value of noncontrast series at the expense of increased dose.	***

Note: Rating scale: 1, 2, 3 = usually not appropriate; 4, 5, 6 = may be appropriate; 7, 8, 9 = usually appropriate. FDG-PET = positron emission tomography using fluorine-l8-2-fluoro-2-deoxy-D-glucose imaging; IV = intravenous; RRL = relative radiation level.

#### Download English Version:

## https://daneshyari.com/en/article/5726503

Download Persian Version:

https://daneshyari.com/article/5726503

<u>Daneshyari.com</u>